Last Updated: November 21, 2026

dificid Drug Patent Profile

« Back to Dashboard


When do Dificid patents expire, and when can generic versions of Dificid launch?

Dificid is a drug marketed by Cubist Pharms Llc and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in DIFICID is fidaxomicin. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the fidaxomicin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dificid

A generic version of dificid was approved as fidaxomicin by ACTAVIS LABS FL on January 16th, 2024.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for dificid?
  • What are the global sales for dificid?
  • What is Average Wholesale Price for dificid?
Recent Clinical Trials for dificid

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of AlbertaPhase 2
Vancouver Island Health AuthorityPhase 3
McMaster UniversityPhase 3

See all dificid clinical trials

Pharmacology for dificid
Paragraph IV (Patent) Challenges for DIFICID
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DIFICID Tablets fidaxomicin 200 mg 201699 1 2015-05-27

US Patents and Regulatory Information for dificid

dificid is protected by five US patents and one FDA Regulatory Exclusivity.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc DIFICID fidaxomicin FOR SUSPENSION;ORAL 213138-001 Jan 24, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cubist Pharms Llc DIFICID fidaxomicin TABLET;ORAL 201699-001 May 27, 2011 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cubist Pharms Llc DIFICID fidaxomicin FOR SUSPENSION;ORAL 213138-001 Jan 24, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cubist Pharms Llc DIFICID fidaxomicin TABLET;ORAL 201699-001 May 27, 2011 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cubist Pharms Llc DIFICID fidaxomicin FOR SUSPENSION;ORAL 213138-001 Jan 24, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cubist Pharms Llc DIFICID fidaxomicin FOR SUSPENSION;ORAL 213138-001 Jan 24, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cubist Pharms Llc DIFICID fidaxomicin FOR SUSPENSION;ORAL 213138-001 Jan 24, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for dificid

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Tillotts Pharma GmbH Dificlir fidaxomicin EMEA/H/C/002087Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents. Authorised no no no 2011-12-05
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for dificid

See the table below for patents covering dificid around the world.

Country Patent Number Title Estimated Expiration
Austria E516024 ⤷  Start Trial
Australia 2003251902 ⤷  Start Trial
Australia 2005327308 ⤷  Start Trial
Australia 2006304868 ⤷  Start Trial
Australia 2008209580 ⤷  Start Trial
Belgium 2015C017 ⤷  Start Trial
Brazil PI0511119 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for dificid

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1539977 C300727 Netherlands ⤷  Start Trial PRODUCT NAME: FIDAXOMICINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205
1539977 CA 2015 00020 Denmark ⤷  Start Trial PRODUCT NAME: FIDAXOMICIN ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/11/733/001-004 20111205
1539977 92684 Luxembourg ⤷  Start Trial PRODUCT NAME: FIDAXOMICINE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/11/733/001-002-004 - DIFICLIR
1539977 15C0028 France ⤷  Start Trial PRODUCT NAME: FIDAXOMICINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111207
1539977 300727 Netherlands ⤷  Start Trial DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
1539977 CR 2015 00020 Denmark ⤷  Start Trial PRODUCT NAME: FIDAXOMICIN; REG. NO/DATE: EU/1/11/733/001-004 20111207
1539977 16/2015 Austria ⤷  Start Trial PRODUCT NAME: FIDAXOMICIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/733/001 - 004 (MITTEILUNG) 20111207
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

DIFICID Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: November 3, 2026

DIFICID, the brand name for fidaxomicin, is a narrow-spectrum macrolide antibiotic used to treat Clostridioides difficile infection, or CDI, in adults and pediatric patients aged six months and older. Its commercial position is supported by guideline preference, low systemic absorption, and lower recurrence rates than oral vancomycin. Its main constraints are high acquisition cost, hospital formulary controls, generic vancomycin competition, and the emergence of microbiota-based recurrence therapies.

Merck owns DIFICID through its acquisition of Cubist Pharmaceuticals, which acquired Optimer Pharmaceuticals, the original developer. Merck does not report DIFICID revenue as a separate line item, so the product’s precise annual sales and profit contribution are not publicly disclosed.

What is DIFICID and how does the drug compete in CDI?

DIFICID contains fidaxomicin, a macrocyclic antibiotic that inhibits bacterial RNA polymerase. It is administered orally and has minimal systemic absorption.

Attribute DIFICID profile
Active ingredient Fidaxomicin
Brand owner Merck & Co., through Cubist
Original developer Optimer Pharmaceuticals
FDA approval May 27, 2011
Main indication Treatment of C. difficile-associated diarrhea
Adult dosage 200 mg orally twice daily for 10 days
Pediatric formulation 40 mg/5 mL oral suspension
Primary comparator Oral vancomycin
Commercial setting Hospitals, specialty infectious-disease care, outpatient treatment
Key value proposition Lower CDI recurrence relative to vancomycin in major trials

The 2021 focused update from the Society for Healthcare Epidemiology of America and Infectious Diseases Society of America recommends fidaxomicin rather than a standard course of vancomycin for an initial CDI episode when resources allow. The recommendation is stronger for recurrent CDI, where fidaxomicin’s recurrence profile is commercially important [1].

DIFICID competes against:

  • Generic oral vancomycin, which has a substantially lower acquisition cost.
  • Vancomycin taper-and-pulse regimens for recurrence.
  • Bezlotoxumab, an intravenous adjunct used to reduce recurrence risk.
  • REBYOTA, approved in 2022 as a microbiota-based live biotherapeutic for prevention of recurrent CDI.
  • VOWST, approved in 2023 as an orally administered fecal microbiota product for recurrent CDI prevention.

These products do not all occupy the same treatment stage. DIFICID is an acute treatment, while REBYOTA and VOWST are generally used after antibacterial treatment to prevent recurrence.

How large is the DIFICID market?

The addressable market is clinically significant but commercially constrained by treatment duration and reimbursement.

The United States experiences hundreds of thousands of CDI cases annually, with recurrent disease affecting a material share of treated patients. The Centers for Disease Control and Prevention identifies CDI as a major healthcare-associated infection and estimates that the infection produces substantial hospital and outpatient burden [2].

DIFICID’s commercial demand is shaped by five factors:

  1. High CDI incidence. Hospitals, skilled nursing facilities, and outpatient settings generate recurring demand.
  2. Recurrence reduction. Fidaxomicin has a clinical advantage over vancomycin in recurrence outcomes.
  3. Guideline support. IDSA/SHEA recommendations favor fidaxomicin when access and resources permit.
  4. Budget pressure. Payers and hospitals often restrict use because generic vancomycin is cheaper.
  5. Recurrence-treatment expansion. Microbiota products create a new category that may reduce some downstream antibiotic use but also expands spending around recurrent CDI.

DIFICID is therefore a premium, guideline-supported product rather than a high-volume broad-spectrum antibiotic.

What is the financial trajectory for DIFICID?

Merck does not disclose DIFICID revenue, gross margin, operating profit, or regional sales separately in its annual reports. The product is grouped within broader pharmaceutical reporting categories. Public financial analysis cannot support a company-verified annual DIFICID revenue series.

The commercial trajectory can be divided into four phases:

Period Commercial phase Main driver
2011-2013 Specialty launch Premium positioning against vancomycin
2013-2015 Cubist ownership Expansion of hospital sales infrastructure
2015 onward Merck ownership Global commercialization and portfolio integration
2021 onward Post-regulatory exclusivity Increasing generic and formulary pressure

Optimer’s development and commercialization economics changed materially when Cubist acquired the company in 2013. Cubist paid approximately $535 million for Optimer, including debt and equity-related consideration, according to contemporaneous transaction reporting [3]. Merck subsequently acquired Cubist for approximately $9.5 billion in enterprise value, bringing DIFICID into Merck’s infectious-disease portfolio [4].

The product likely reached its commercial maturity before or around the end of regulatory exclusivity. After 2021, revenue growth became more dependent on:

  • Guideline-driven prescribing;
  • Hospital stewardship protocols;
  • Medicare and commercial reimbursement;
  • Pediatric adoption of the oral suspension;
  • Persistence of brand preference despite generic entry;
  • DIFICID’s ability to retain use in high-risk or recurrent patients.

Because Merck does not separately report DIFICID revenue, any precise annual sales estimate is an analyst estimate rather than a company-disclosed figure.

When did DIFICID lose regulatory exclusivity?

DIFICID received several forms of U.S. regulatory protection.

Protection Approximate timing Commercial effect
New chemical entity exclusivity 2016 expiration Blocked ANDA approval during the initial five-year period
Qualified Infectious Disease Product exclusivity Approximately May 2021 Added five years to the NCE exclusivity period
Pediatric exclusivity Approximately late 2021, if awarded for the qualifying study Could add six months to applicable exclusivity or patent terms
Patent protection Multiple dates depending on patent and claim Potentially extends beyond regulatory exclusivity

DIFICID qualified for the Qualified Infectious Disease Product program under the Generating Antibiotic Incentives Now provisions. QIDP status can provide an additional five years of exclusivity for eligible antibacterial and antifungal products. FDA approved DIFICID in May 2011, placing the likely end of the combined five-year NCE and five-year QIDP period in 2021, subject to the precise statutory calculation and any pediatric extension [5].

Regulatory exclusivity and patent protection are separate. The end of FDA exclusivity did not automatically authorize generic commercial entry if Orange Book-listed patents remained enforceable.

What patents protect DIFICID?

DIFICID’s U.S. intellectual-property estate has included composition, formulation, and use-related patents. Historical Orange Book and public patent records identify patents associated with fidaxomicin and DIFICID that extend beyond the initial 2011 approval period.

Key historical patent families include:

Patent General relevance Reported expiration period
U.S. Patent No. 7,335,773 Fidaxomicin composition and related claims 2025, subject to applicable adjustments
U.S. Patent No. 8,242,104 Fidaxomicin-related pharmaceutical claims 2029, subject to applicable adjustments
Later formulation and use patents Dosage-form, administration, or treatment claims Potentially later than 2029

The commercial significance of the estate depends on claim scope, Orange Book listing status, terminal disclaimers, patent-term adjustment, patent-term extension, and the specific ANDA formulation. A patent covering a particular dosage form may delay a generic tablet but not necessarily block every alternative product, such as an oral suspension or different manufacturing route.

The most valuable patent positions are those that cover:

  • Fidaxomicin itself;
  • Crystalline or polymorphic forms;
  • Tablet composition and dissolution characteristics;
  • Oral suspension formulations;
  • Treatment regimens designed to reduce CDI recurrence;
  • Manufacturing processes that improve purity, yield, or stability.

A generic applicant can challenge some patents while carving out method-of-use claims under a Section viii statement. The practical outcome depends on whether the remaining claims cover the product itself or only a restricted indication.

What is the Orange Book status of DIFICID?

DIFICID’s Orange Book position is more important for generic entry than its historical NCE exclusivity. ANDA applicants must address listed patents through a Paragraph I, II, III, or IV certification, or use a Section viii statement for a method-of-use patent.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. If the patent holder files suit within 45 days, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and litigation developments [6].

The relevant commercial question is not simply whether DIFICID has an unexpired patent. It is whether the unexpired claims:

  • Cover the generic applicant’s exact dosage form;
  • Are listed for the relevant product;
  • Survive invalidity and noninfringement challenges;
  • Can support a 30-month stay;
  • Are broad enough to prevent a commercially viable alternative.

Which companies are challenging DIFICID exclusivity?

Generic drug companies have pursued fidaxomicin development as regulatory and patent barriers matured. Publicly reported ANDA activity has involved multiple generic manufacturers, including applicants associated with Lupin and other large generic companies.

The competitive threat is fragmented rather than concentrated. Fidaxomicin manufacturing is more complex than conventional small-molecule antibiotics because the molecule is fermentation-derived and requires specialized purification and formulation controls. A successful challenger must establish:

  • Pharmaceutical equivalence;
  • Bioequivalence or the applicable FDA standard;
  • Adequate stability;
  • Consistent impurity control;
  • Scalable manufacturing economics;
  • Commercial access to hospital and payer channels.

The first approved generic is likely to face limited immediate volume because hospitals may maintain brand contracts, use restricted protocols, or prefer a particular supplier. Multiple approved generics would create greater price pressure.

What formulation patents protect DIFICID?

DIFICID has two commercially important oral dosage forms:

  1. 200 mg immediate-release tablets.
  2. An oral suspension intended for pediatric patients and others unable to swallow tablets.

The pediatric formulation expands the addressable population but also creates a separate technical and regulatory barrier. A suspension generic must match stability, reconstitution, dosing accuracy, container-closure performance, and microbiological specifications.

Formulation protection can preserve brand value after composition patents expire if the listed claims cover tablet excipients, dissolution characteristics, suspension stability, or a specific manufacturing process. That protection is narrower than a composition patent and may be avoided through a different formulation design.

How does DIFICID compare with oral vancomycin?

Factor DIFICID Oral vancomycin
Brand status Branded product with generic competition emerging Widely available generic
Recurrence profile Lower recurrence in major comparative studies Effective, but higher recurrence in some settings
Acquisition cost Premium Low relative cost
Guideline position Preferred when resources allow Acceptable alternative
Spectrum Narrow activity against C. difficile Active against C. difficile
Hospital access Often restricted Broad access
Commercial risk Generic erosion and reimbursement controls Price competition already established

DIFICID’s premium depends on payers accepting the value of lower recurrence. Hospitals may still select vancomycin when acquisition cost dominates, particularly for lower-risk initial episodes.

What generic launch risks exist for DIFICID?

The likely launch scenarios are:

Scenario 1: Delayed launch after patent settlement

A generic company may secure a license or settlement permitting entry before the latest patent expiration. The agreement could include an authorized generic, supply arrangement, or staggered launch date.

Scenario 2: At-risk launch

A generic applicant may launch before final patent resolution. This exposes the applicant to damages and injunctive risk but can accelerate market entry if the patents are later invalidated or found not infringed.

Scenario 3: Limited product launch

A generic may launch tablets while avoiding a protected suspension formulation or carved-out method of use. This would create partial rather than complete substitution.

Scenario 4: Multi-supplier erosion

Several approved generics could reduce DIFICID pricing and volume rapidly. Hospital contracting would determine whether the erosion resembles a standard small-molecule generic launch or develops more gradually.

What patent litigation and settlement issues affect DIFICID?

DIFICID litigation risk centers on Paragraph IV challenges, Orange Book-listed patents, and whether the generic product practices formulation or composition claims. A settlement could preserve brand revenue by delaying entry while providing the generic applicant a defined launch date.

No broad public settlement framework should be assumed without reviewing the individual court docket and settlement terms. The economic effect depends on:

  • Entry date;
  • Number of settling applicants;
  • Whether the settlement permits an authorized generic;
  • Whether the agreement includes supply or licensing rights;
  • Whether later applicants remain free to launch;
  • Whether FDA approval is blocked by other patents.

What manufacturing and geographic barriers protect DIFICID?

Fidaxomicin is a fermentation-derived active pharmaceutical ingredient. Manufacturing requires control over fermentation, purification, solid-state properties, impurities, and final dosage-form performance.

The principal barriers are operational rather than purely legal:

  • Limited qualified API suppliers;
  • High process-development cost;
  • Complex impurity profile;
  • Batch-to-batch consistency;
  • Specialized analytical methods;
  • Hospital procurement qualification;
  • Regional regulatory filings.

U.S. sales are strategically important because FDA approval, hospital formularies, and Medicare reimbursement shape the largest premium market. European and other markets have different reimbursement systems and may show lower brand pricing or faster substitution.

What is the outlook for DIFICID revenue?

DIFICID is likely to remain a durable but mature specialty antibiotic. Its revenue outlook depends on a balance between clinical preference and price erosion.

Positive factors include guideline support, recurrent-CDI use, pediatric availability, and the medical need for alternatives to vancomycin. Negative factors include generic entry, payer restrictions, microbiota-based therapies, and Merck’s lack of a separately disclosed growth strategy for the product.

The product’s financial trajectory is therefore more likely to show a mature-brand pattern than a high-growth pharmaceutical pattern:

  • Stable demand while formulary preference persists;
  • Gradual pressure as generic suppliers enter;
  • Faster erosion if multiple ANDA products launch simultaneously;
  • Residual premium pricing in recurrent or high-risk patients;
  • Declining strategic importance relative to Merck’s oncology, vaccine, and cardiopulmonary portfolios.

Key Takeaways

  • DIFICID is fidaxomicin, a premium oral antibiotic for CDI.
  • Merck owns the product through the Cubist-Optimer acquisition chain.
  • Merck does not separately disclose DIFICID revenue or profit.
  • FDA approval occurred in 2011; combined NCE and QIDP exclusivity likely ended in 2021, subject to statutory and pediatric adjustments.
  • Historical patent protection extends beyond regulatory exclusivity, with key patent dates reported in the 2025-2029 range and later formulation or use claims potentially extending beyond that period.
  • Generic risk is real but may develop gradually because fidaxomicin manufacturing, hospital contracting, and formulation requirements are specialized.
  • Oral vancomycin remains the main price competitor.
  • REBYOTA and VOWST compete mainly in recurrence prevention rather than acute CDI treatment.
  • DIFICID’s long-term value depends on guideline-driven use, reimbursement, recurrence reduction, and the timing of generic entry.

FAQs About DIFICID Market Exclusivity and Competition

Is DIFICID still under patent protection?

Historical U.S. patents associated with DIFICID extend beyond the end of FDA regulatory exclusivity. The commercial effect depends on which claims remain enforceable and whether they cover the generic applicant’s product.

Does DIFICID have a generic equivalent?

Generic fidaxomicin development and ANDA activity have progressed after the end of the principal regulatory exclusivity period. Actual substitution depends on FDA approval, patent litigation, settlements, and commercial launch decisions.

Why is DIFICID more expensive than vancomycin?

DIFICID is a branded, differentiated antibiotic with clinical evidence supporting lower recurrence. Oral vancomycin is widely available from generic manufacturers, producing a substantially lower acquisition cost.

Does DIFICID prevent recurrent C. difficile infection?

DIFICID treats active CDI and reduces recurrence relative to standard oral vancomycin in major studies. It is not the same type of recurrence-prevention product as REBYOTA or VOWST.

Is Merck’s DIFICID revenue publicly available?

No. Merck reports DIFICID within broader pharmaceutical categories and does not provide a separate annual revenue or operating-profit line for the product.

References

  1. Johnson, S., Lavergne, V., Skinner, A. M., et al. (2021). Clinical practice guideline by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America: 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases, 73(5), e1029-e1044. https://doi.org/10.1093/cid/ciab549

  2. Centers for Disease Control and Prevention. (2024). C. diff: Facts for clinicians. https://www.cdc.gov/c-diff/hcp/clinical-overview/

  3. Reuters. (2013, August 5). Cubist to buy Optimer for $535 million. Reuters.

  4. Merck & Co., Inc. (2015). Merck completes acquisition of Cubist Pharmaceuticals. https://www.merck.com

  5. U.S. Food and Drug Administration. (2024). Qualified infectious disease product designation. https://www.fda.gov

  6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.